Efficacy and Safety of Melatonin as Prophylaxis for Migraine in Adults: A Meta-analysis
Puliappadamb HM, Maiti R, Mishra A, Jena M
Published in Journal of Oral & Facial Pain and Headache
Methodology
PRISMA-guided meta-analysis of three randomized trials of melatonin for adult migraine prophylaxis, with Cochrane risk-of-bias assessment and subgroup analysis by comparator.
Key Findings
Melatonin raised responder rates versus placebo and standard therapy (OR 1.84) and reduced attack frequency, duration, analgesic use and severity versus placebo, but showed no advantage over amitriptyline or valproate.
Conclusions
Melatonin is a reasonably tolerated prophylactic option that beats placebo but does not outperform established preventives.
Limitations
Only three trials pooled, small total sample, heterogeneous comparators, and imprecision in effect estimates.
Supplements Studied
Melatonin therapy in migraine was associated with a significantly higher responder rate when compared to both placebo and standard therapy (OR = 1.84; 95% CI: 1.08 to 3.14; P = .03).
Related Health Concerns
Study Details
Access Study
Disclosures
Funding
Not stated
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.